PHR vs HCAT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

PHR

46.1
AI Score
VS
HCAT Wins

HCAT

56.9
AI Score

Investment Advisor Scores

PHR

46score
Recommendation
HOLD

HCAT

57score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PHR HCAT Winner
Revenue 260.39M 141.24M PHR
Net Income 4.88M -151.56M PHR
Net Margin 1.9% -107.3% PHR
Operating Income 14.36M -142.96M PHR
ROE 1.3% -150.3% PHR
ROA 0.8% -42.3% PHR
Total Assets 646.98M 358.60M PHR
Debt/Equity 0.00 1.52 PHR
Current Ratio 1.76 2.70 HCAT
Free Cash Flow 37.45M 18.10M PHR

Relative Price Performance (Last 90 Days)

PHR 1M: +21.4% · 3M: +25.1% HCAT 1M: -7.9% · 3M: -13.4%

Current Technical Phase

PHR

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 73

RSI (14): 72.9 · Price: $12.26

HCAT

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -7.8%) with fading momentum, RSI 48

RSI (14): 48.2 · Price: $1.74

Fundamentals Snapshot

Metric PHR HCAT
Market Cap — —
Forward P/E 8.1 232.0
Trailing P/E 66.9 —
Revenue (TTM) — —
Revenue Growth 0.1% -0.1%
Gross Margin 0.7% 0.5%
Operating Margin 0.1% -0.1%
EPS 0.18 -3.69
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HCAT is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.